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REVIEW
OBSTRUCTIVE SLEEP APNEA AND INSULIN
RESISTANCE: A ROLE FOR MICROCIRCULATION?
Nicolas Wiernsperger, Pierre Nivoit, and Eliete Bouskela
Wiernsperger N, Nivoit P, Bouskela E. Obstructive sleep apnea and insulin resistance: a role for microcirculation? Clinics.
2006;61(3):253-66.
Obstructive sleep apnea is an increasingly recognized medical problem. The recent attention to its frequency in the general
population and its important role in metabolic, vascular, and behavioral aspects have sharply increased the number and nature of
investigations, thereby revealing new aspects that open new approaches in research. Whereas obstructive sleep apnea is a well-
known phenomenon accompanying obesity and diabetes, new findings strongly suggest that this close relationship may also
operate in the opposite direction. Indeed obstructive sleep apnea may be a primary feature inducing or aggravating a series of
vascular and metabolic disturbances closely resembling the metabolic syndrome. This review will discuss established and potential
mechanisms responsible for these changes. Obstructive sleep apnea indeed appears to gather all the elements necessary to induce
insulin resistance, hypertension, and possibly heart failure. After careful analysis of these modifications and considering how they
are intertwined, we propose that microcirculation could represent the common denominator mediating the progression of this
pathology, as it is eventually the case in the metabolic syndrome and diabetes domain. This plausible hypothesis is discussed in
detail and should be verified by appropriate preclinical and clinical protocols, which are now achievable by using noninvasive
techniques in humans.
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INTRODUCTION
Few domains of medicine have experienced so much
interest as obstructive sleep apnea (OSA) over the last 10
years. The sharp rising interest in this phenomenon started
when it was first suggested that OSA may not just be an
accompanying symptom but might cause or aggravate meta-
bolic and vascular diseases.
Sleep disordered breathing comprises several processes
that provoke repetitive interruptions in sleep, mainly due
to snoring and hypopneas/apneas of either central or OSA
origin. Epidemiologically, the OSA syndrome affects prob-
ably about 5% of the general population. The prevalence
of OSA is much higher in diseases as common as hyper-
tension (22-48%)1 or heart failure (11-37%). In this latter
group, central apneas are seen in 45% of subjects2 and are
inversely related to cardiac ejection fraction. Half of the
patients with diastolic heart failure have an increase in the
number of apneas.
The present review will describe the most recent knowl-
edge about links between obstructive sleep apnea and
cardiometabolic disorders. In particular, the possibility that
this relationship operates in both directions is a recent view
that strongly stimulates interest in new preclinical and clini-
cal research. We will also discuss the plausible hypothesis
that the microcirculation may be the common denomina-
tor of these intertwined disturbances.
OSA IS A SERIOUS CLINICAL CONDITION
Apneas are either complete or incomplete (hypopneas),
which has led to the creation of a so-called apnea/hypopnea
index (AHI) that permits the evaluation of frequency of
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apneas in patients. Obstructive sleep apneas are of mechani-
cal origin, due to the failure of upper airways to maintain
their muscle tone. Not surprisingly OSAs are most frequent
in obese individuals, as a consequence of fat deposition in
the muscles of the upper airways. Almost all OSA subjects
exhibit intense snoring, but snoring is not necessarily ac-
companied by OSA. This is important in clinical trials,
which partly were based on this indirect parameter. The link
between OSAs and obesity is strong, such as to bias many
protocols and interpretations of older clinical studies. A
10% increase in body weight over 4 years increases the risk
for OSA 6-fold.3 Recent findings revealed that half of the
genetic variance in OSA is shared with obesity phenotypes,4
which may have important consequences, as will be dis-
cussed later. Obstructive sleep apneas are more frequent
during REM sleep,5 and their number, usually of short du-
ration (around 20 s) can reach several hundred per night.
Sleep apneas up to 1 min can be found, a situation that
may be life-threatening. Each sleep apnea is characterized
by hypoxia during breathlessness, with blood oxygen satu-
ration (SaO2) down to 50% in extreme cases. The degree
of desaturation is at least as important as the total number
of episodes for complications linked with OSA. Each epi-
sode is followed by an arousal reaction restoring breath,
thereby inducing abrupt reoxygenation. Patients with OSA
suffer daytime sleepiness, a situation closely linked to car
accidents, especially in the late afternoon.
OSA and Insulin Resistance / Glucose Tolerance /
Diabetes
There is a very close link between insulin resistance
(IR) and OSA, but causative mechanisms are disputed.6,7
It was well-known that snoring and OSA are essentially
seen in overweight/obese patients characterized by IR or
the metabolic syndrome; more recent investigations sup-
port this link by showing that other diseases characterized
by IR are also linked with OSA: in patients with polycystic
ovary syndrome, elevated insulin levels and impaired glu-
cose tolerance correlated with a higher frequency of OSAs,
and this correlation was even independent of BMI in glu-
cose normotolerant women.8,9 Similarly, OSA affects about
two thirds of acromegalic patients.10,11 Nonalcoholic
steatohepatitis (NASH), a situation found in most IR-pa-
tients, is also linked to severe OSA, with patients having
high AHI values being more insulin-resistant and exhibit-
ing more steatosis as well as elevated liver enzymes.12 Il-
lustrating the close relationship between IR and obstruc-
tive sleep apnea, it was proposed that OSA should be added
to syndrome X (metabolic syndrome) and the new entity
be called syndrome Z.13 A main question is still whether
this correlation is simply due to—or is independent of—
excess fat (BMI or visceral fat). Table 1 shows how OSA
superimposed on obesity worsens various metabolic and
vascular parameters.
Indeed, several studies have claimed the correlation to
be strictly due to the presence or absence of concomitant
obesity in children14 and adults.15 In contrast, more recent
studies suggest that whereas obesity plays a role, elevated
AHI and minimum SaO2 values are important determinants
of impaired glucose tolerance.16 In these patients, each ad-
ditional apneic episode increased plasma insulin and the
HOMA-index by 0.5%. In another study, the degree of glu-
cose intolerance was related to the severity of desaturation.
It was estimated that each 4% drop in SaO2 represented an
odds ratio of 1.99 for glucose intolerance.17 Independently
of BMI, fasting insulin—an indirect indicator of IR—cor-
related with OSA severity.18
However, here again, a bias in interpreting such data
lies in the fact that a sleep debt per se, such as frequently
interrupted sleep or shortened sleep duration without
breathing abnormalities, also leads to IR.19 Indeed, patients
submitted to sleep debt exhibit a higher HOMA index, ab-
normal glucose tolerance, and a reduction in first-phase in-
sulin secretion.20 Therefore, some of the mechanisms in-
volved might also be due to sleep deprivation rather than
strictly hypoxia/reoxygenation. In the recent Sleep Heart
Health Study, the odds ratio for fasting glucose intolerance
was 1.7 for mild and 1.46 for severe OSA, and this corre-
lated with SaO2. In this large-scale clinical investigation,
OSA was independently associated with glucose intoler-
ance, IR, and noninsulin-dependent diabetes mellitus.21 In
another trial, fasting and postload glycemia increased with
OSA severity, with a concomitant decrease in insulin sen-
sitivity.22 Recently, it was shown that a high fat diet in nor-
mal rats was followed by sleep apneas.23
In diabetic patients, the elevated number of sleep apneas
appears to be predominantly of central rather than obstruc-
tive origin, likely because of the frequent presence of au-
Table 1 - Additional effects of obstructive sleep apnea (OSA)
on metabolic and vascular parameters in obesity. Data on
control (healthy) subjects and obese patients without OSA
are also shown (adapted from ref. 6)
C Ob Ob + OSA
BMI 26 36 38
MABP 92 102 107
Visceral fat area 220 337*
Total wake time 66 59 113
REM latency 74 82 93
Minimum O2 saturation 94 91 74
255
CLINICS 2006;61(3):253-66 Obstructive sleep apnea and insulin resistance: a role for microcirculation?
Wiernsperger N et al.
tonomic neuropathy in this disease. Poor sleep quality in
diabetic patients is related to higher HbA1C values.24
OSA and Cardiovascular Diseases
Mortality is greater in patients having AHI values
greater than 20.25,26 Obstructive sleep apnea severely affects
cardiac function in compromised hearts. The Sleep Heart
Health Study showed that cardiovascular diseases (CVD)
were more frequent in OSA patients, even in those with
moderate AHI values.27 In this cross-sectional study per-
formed on more than 6000 subjects, a strong correlation
was established between AHI and the prevalence of CVD
(coronary heart diseases, heart failure, and stroke).27 Ob-
structive sleep apnea at baseline is a significant predictor
of CVD, and a recent study showed that the CVD incidence
was 57% in untreated vs 7% in efficiently treated OSA pa-
tients.28 In addition to hypertension, OSA patients have a
58% prevalence of cardiac arrhythmias.1 Acute experimen-
tal OSA leads to arterial stiffness.29 Chronic OSA patients
accordingly show diminished aortic distensibility and have
an increased stiffness index.30 Patients with OSA spending
9% of the night time with SaO2 below 90% exhibit carotid
wall hypertrophy.31
OSA, METABOLIC DERANGEMENTS, AND CVD:
A BIDIRECTIONAL PROCESS?
As briefly stated above, the increase in OSA in patients
suffering from IR/diabetes or severe cardiac pathologies is
a well-known clinical observation. Additionally, OSA is
likely to aggravate preexisting diseases. The first clinical
studies were biased by confounding factors, mainly the
presence of obesity, but also by subjective self-answered
questionnaires or self-reporting of snoring. Later studies
using more careful patient observations (eg,
polysomnography and blood sampling during apneas) and
improved matching of patients control groups, as well as
experimental investigations, suggested that OSA might in-
duce by itself—or intensify—the switch towards diabetes
and lead to macrovascular complications.32
Do OSAs Induce Insulin Resistance?
A main question is whether OSA can be causal to the
metabolic- and vascular-related disturbances (Fig.1). In
snoring children19 and adults,33 higher insulin levels are
present, usually revealing IR. Fasting insulin levels corre-
late with OSA.34 Nonobese patients suffering from OSA
have more visceral fat35 and diminished adiponectin,36 both
major situations favoring IR and vascular disturbances. Pio-
neering studies have recently suggested that the presence
of the ApoEe4 allele might predispose to OSA, and the
presence of this genetic variation also in Alzheimer’s dis-
ease raises the possibility that OSA might, via recurrent
hypoxic episodes, be involved in the cognitive deteriora-
tion affecting these patients.37 Humans exposed to high al-
titude hypoxia exhibit decreased insulin sensitivity, indi-
cating that hypoxia per se is able to generate IR.38 Even
acute hypoxia for 30 min at a SaO2 < 75% leads to a de-
crease in glucose disposal rate.39 Interestingly, such data
are similar to what is observed in hypoglycemia, despite
major differences in stress hormone profiles, thus pointing
again towards a specific role for hypoxia. Here also, sleep
deprivation per se may play a role, since short sleepers have
an odds ratio of 2 for developing IR.40
In preclinical experiments, the main features of OSA
can be simulated by sophisticated technical devices allow-
ing repetitive and abrupt adjustable changes in respiratory
gas in chambers. This procedure is called intermittent hy-
poxia (IH). In vitro, cultured cells can be exposed to se-
lected levels of oxygenation. For example, IH or fructose
feeding (another way to induce IR) both reduce the
ventilatory response to hypoxia and hypercapnia and lead
to elevated insulin concentrations41 and reduced insulin sen-
sitivity.38,42 Interestingly, IH worsens—while continuous
hypoxia improves—glucose tolerance, suggesting that re-
petitive cycles of low and high oxygen play a determining
role.38
Do OSAs Favor Diabetes?
Occasional and regular snoring increases the risk of
diabetes by 1.5 and 2.25 respectively.43 The incidence of
diabetes was doubled over 10 years in middle-aged, ha-
bitual snorers.44 In a paper that just appeared, a prospec-
tive study, the Wisconsin Sleep Cohort, comprising 1387
Figure 1 - Scheme illustrating the actual hypothesis of possible bidirectional
relationships between obstructive sleep apneas (OSA), insulin resistance,
and cardiovascular (CVD) disorders
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patients, evaluated the prevalence and the incidence of
type 2 diabetes in subjects with OSA. It appeared that the
odds ratio for developing diabetes within 4 years was 1.62
with an AHI > 15, compared with subjects with AHI < 5
after adjustments for age, sex, and body habitus.45 The
prevalence of diabetes in subjects with AHI > 15 was
14.7%, as compared with 2.8% in those with AHI < 5.
Although this study does not constitute a definitive proof,
such data strongly argue for a causal role of OSA in dia-
betes development.
Do OSAs favor Cardiovascular Diseases?
One of the most striking cardiovascular complications
of OSA is hypertension. The sympathetic discharge accom-
panying hypoxia/reoxygenation induces vascular resistance
which does not resume during daytime.1,40 Therefore, there
is a state of persistent chemoreceptor activation.32 The hy-
pertension induced by OSA has a particular profile:
diastolic pressure increases early, and patients experience
no diurnal variation of systemic blood pressure. Impor-
tantly, there is also no nocturnal dipping of blood pressure.
This type of hypertension severely affects the brain and
heart, with little effect on the kidneys.46 Otherwise healthy
patients suffering from OSA show increased body weight
and sympathetic muscle activity.47 Stroke and cardiac ar-
rest in the early morning hours are other typical features
of OSA: a lack of normal reaction of brain vessels to
isocapnic hypoxia during non-REM sleep could explain the
vulnerability of these subjects towards stroke.48
In mice, chronic IH increases blood pressure and
hematocrit as well as the weights of the left and right ven-
tricle and septum, signs of right heart loading and pulmo-
nary vasoconstriction.49,50 The same profile is found in hu-
mans: 25% of OSA patients have mild pulmonary hyper-
tension; 18% suffer right ventricular dysfunction, and they
have a 3-fold increase in risk for CVD.51 The susceptibil-
ity of hearts to infarction was increased in rats subjected
to 35 days of IH.52 Here again, IH is more detrimental than
sustained hypoxia for increasing blood pressure and sym-
pathetic activation.53 Obstructive sleep apnea also leads to
elevated levels of NPY, another factor of vasoconstriction.54
In a study in rats, the IH-induced hypertension was found
to last several weeks after cessation of the procedure.55 Each
additional incident of apnea increased the odds ratio for
hypertension by 1%.56 This striking link between OSA and
hypertension57, as well as that between OSA, congestive
heart failure and respiratory alterations58 have been widely
reviewed recently.
Figure 2 summarizes the main potential consequences
of OSAs on metabolic and vascular parameters.
MECHANISMS OF OSA-INDUCED METABOLIC
AND VASCULAR DISORDERS
The similarity of OSA-related pathologies with meta-
bolic syndrome is striking: in addition to hypertension, risk
factors for atherosclerosis, inflammation (cytokines),
hemostatic disorders, oxidative stress, and defects in vas-
cular reactivity are among the major common features. The
following chapter will document the major recent findings
in biochemical and cellular mechanisms underlying these
complications.
Inflammation / Adhesion Molecules
As in metabolic syndrome, a mild inflammatory state
characterizes OSA.1 Indeed, several studies have reported
an increase in CRP, IL-6, IL-8, or TNFα in patients with
OSA.59–61 In adolescents free of CVD but with an AHI > 5,
CRP levels were increased even after adjustment for the
confounding obesity factor.62 Interestingly, partial sleep
deprivation also increases CRP levels.63 TNFα levels are
also elevated in serum and monocytes.60,61,64,65 Post apnea,
Figure 2 - Main cardiometabolic consequences of obstructive sleep apneas
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TNFα increases immediately after SaO2 reaches a thresh-
old of 85%.66 Moreover, the TNFα circadian rhythm is dis-
turbed (less during night, more during day).67 These mol-
ecules are known to be closely linked with IR and predic-
tive of type 2 diabetes.68 Adhesion molecules such as
ICAM-1, VCAM-1, or E-selectin are also increased in pa-
tients suffering from OSA.1,69 A particular role for CD11c
and CD15 has been recently proposed.70
Adipokines
Several studies have demonstrated an increase in cir-
culating leptin levels in OSA patients, which correlates with
SaO2.71 Indeed, it has been shown that leptin rises in order
to compensate for IH.38 The leptin increase is seen even in
otherwise healthy subjects suffering from OSA.47 High
plasma soluble leptin receptor concentrations and reduced
glucose uptake are correlated with OSA, and globally there
seems to exist an inverse correlation between insulin sen-
sitivity and leptin receptor concentration.33,72 Another sub-
stance liberated by fat cells is adiponectin, the role of which
is increasingly considered to be protective against IR and
vascular disturbances. In OSA patients, in addition to in-
creases in hsCRP and IL-6, adiponectin levels were re-
duced36; however, another study reported the opposite.73
This should be taken into account, since leptin is consid-
ered important in IR and promotes oxidative stress, another
potential factor involved in prediabetes and diabetes (see
below).74,75
HIF-1 Alpha
Intermittent hypoxia, even in vitro, increases levels of
hypoxia-inducible factor 1 alpha (HIF-1 alpha).76 While
HIF-1 might first increase as a protective, compensatory
mechanism,77 its sustained liberation may have deleterious
effects77: indeed, HIF-1 is able to reduce eNOS (the en-
dothelial isoform of nitric oxide synthase) and increase
iNOS (inducible nitric oxide synthase) and VEGF (vascu-
lar endothelial growth factor), with possible consequences
to vascular reactivity and permeability.77-80
Hemostasis
Blood platelets are activated and aggregate in OSA.1
The blood coagulation system is activated by acute hy-
poxia.81 Type III procollagen, as seen in NASH, correlates
with SaO2.71 Patients with reduced SaO2 have elevated D-
dimer concentrations, indicating defects in the fibrinolytic
system.82
Lipid Metabolism
Intermittent hypoxia leads to increased levels of total
cholesterol, phospholipids, and triglycerides in normal ani-
mals. However, no further aggravation was seen if animals
were already hyperlipidemic.83 In vitro, IH also leads to li-
pid loading of macrophages, a process critical for the de-
velopment of atherosclerosis.84
Vascular Reactivity, Endothelin, Nitric Oxide
Patients with moderate to severe AHI values show re-
duced endothelial function and a strong correlation between
both parameters.85 The endothelium-dependent vasodilata-
tion in response to acetylcholine or bradykinin is reduced,
while endothelium-independent vasodilatation is unaf-
fected.86,87 Another study found this defect only in small
resistance vessels but not in conduit vessels.88 Impaired en-
dothelium-dependent vasodilatation may be due to a de-
fect in nitric oxide (NO) production and/or an excess of
vasoconstrictor molecules. In fact, both are seen in OSA:
NO production is reduced88,90 (Fig. 3), and endothelin 1 (and
possibly 2) is increased. In vitro, hypoxia reduces eNOS
activity,91 and in vivo, basal NO release is decreased in
arterioles of rats chronically submitted to IH.92 In addition,
plasma levels of ADMA (plasma asymmetric
dimethylarginine), an arginine metabolite that interferes
with normal arginine uptake, are increased.93
As for endothelin, several groups have reported in-
creases in endothelin-1 in sleep deprivation93 and OSA.94,95
Others have reported increases in big endothelin-1.96,97 In-
terestingly, experimental IH-induced hypertension showed
an oversensitivity in vascular constriction that was selec-
tive towards endothelin.98 Endothelin is indeed a powerful
vasoconstrictor98 that may be responsible for IH-induced
Figure 3 - Reduction in nitric oxide (NO) production in persons with
obstructive sleep apnea (OSA) as compared to normal (N) controls (adapted
from ref. 89)
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hypertension.99 It may also induce oxidative stress by gen-
erating superoxide via NADPH oxidase activation.100,101 In
contrast, one clinical investigation failed to find endothelin-
1 modifications in patients with OSA.102 Thus, despite some
remaining controversy, most data points towards an impor-
tant implication of endothelin in peripheral vascular resist-
ance and hypertension in OSA.
Oxidative Stress
The occurrence of multiple cycles of hypoxia/
reoxygenation occurring in OSA patients raises the ques-
tion of oxidative stress as a logical, main cause of the com-
plications found in this pathology. Indeed, both hypoxia per
se and, more expectedly, the reoxygenation phase are prone
to produce free radicals102; in particular superoxide pro-
duced by mitochondria during hypoxia acts as an oxygen
sensor for adaptive mechanisms to limit the harmfulness
of low oxygen.103–109 Oxygen species released during hy-
poxia may act as signalling molecules and have been pos-
tulated to resemble a preconditioning stimulus.110 It is
known from the impressive amount of literature on
oxidative stress that this phenomenon is linked to all un-
desirable side effects associated with OSA. For example,
provoking oxidative stress in rats leads to vasoconstriction,
to an increase in blood pressure, and a reduction in NO
production.111 If animals are already insulin-resistant
(Zucker rats), administration of a pro-oxidant for some days
switches IR to frank diabetes.112
Surprisingly, however, the role of oxidative stress in
OSA is controversial. Investigations about the occurrence
and extent of oxidative stress in OSA have, paradoxically,
generated conflicting results. In animals, sleep deprivation
reduced glutathione levels in the thalamus and
hypothalamus.113 Chronic IH led to left ventricular dilata-
tion with increased lipid peroxides and lower superoxide
dismutase levels.114 The so-called “ reductive stress” ob-
served during hypoxia is mediated by NADPH oxidase, the
gene and protein expression of which is increased in IH.115
Conversely, in mice with no or suppressed capacity to pro-
duce NADPH oxidase, no lipid peroxidation or inflamma-
tory reaction could be observed.115 However, in humans,
data are more controversial; the production of superoxide
was increased in neutrophils of OSA patients,116 and 8-
isoprostane was elevated in the breath condensate in a man-
ner correlating with AHI values.117 In contrast, several stud-
ies failed to document oxidative stress; susceptibility of
LDL (low-density lipoprotein) to oxidation, which is an in-
direct way to detect oxidative stress, was not different from
controls.118 Another study could detect neither differences
in lipid peroxidation nor diminished superoxide dismutase
levels.119 Very recently, a clinical study dedicated to this
topic completely failed to find changes in oxidized LDLs,
thiobarbituric acid reactive substances, or isoprostanes,
which are different substances that reflect various possible
sources/targets of oxidative stress.120
Oxidative stress may precede endothelial dysfunction
and IR,121 which makes it an attractive candidate. However,
it seems that in humans, against expectations, there is pres-
ently no firm evidence for oxidative stress, at least as a
chronic pathological defect.122 Considering on one hand the
complexity of this field and its numerous contradictions121
and, on the other hand, the possibility that local, repeti-
tive, and transient peaks of oxidative stress are not neces-
sarily translated into permanently measurable defects, a
definitive conclusion should not be drawn here. Alterna-
tive explanations may also exist. For example, early IR pri-
marily occurs in the skeletal muscles, but we ignore
whether the insult developing in OSA is sufficient to in-
duce severe abnormalities in this tissue: a recent paper
showed that, at least globally, oxygen levels in muscle tis-
sue did not reach critical anaerobic levels during systemic
hypoxia close to levels observed in OSA.123 Finally, because
stress reactions are induced at the gene level, it could be
that such mechanisms can compensate for the hypoxic
stimulus over long periods of time.
OSA, IR, AND CVD: IS MICROCIRCULATION THE
CLUE?
The similarities between metabolic syndrome (syn-
drome X) and OSA are striking. If we do not consider the
literature about OSA in IR or diabetes but take it from the
point of view of OSA as the primary defect, we observe
the same profile of disturbances as described for IR and
its associated vascular pathologies.
Sympathetic Activation and Its Consequences
Experimental IH and clinical OSAs lead to elevated
sympathetic tone that persists during the daytime.124,125
Muscle sympathetic nerve activity and its chemoreflex con-
trol are also chronically elevated.126,127 Evidently, sympa-
thetic activation will also translate into elevated heart rate
and blood pressure as well as left ventricular thickness,
eventually leading to cardiac failure. Activation of the cen-
tral sympathetic nervous system and activation of the
hypothalamic-pituitary-adrenal axis, which is also increased
in OSA,128 are known factors responsible for the develop-
ment of HT, cortisol elevation, and IR.129 Furthermore the
sympathetic nervous system controls organs such as the
liver and the pancreas, which are closely involved in insu-
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lin and glycemia regulation.130,131 In addition, insulin, which
increases in OSA, is itself able to stimulate the sympathetic
system. Higher levels of heart rate and pulse pressure are
responsible for a phenomenon called “hyperdynamic cir-
culation,” which is linked to the metabolic syndrome131,132
and adverse cardiovascular risks.133,134 Interestingly, hyper-
dynamic circulation occurring in parents predicts IR in their
children.135
Left ventricular relative wall thickness is inversely cor-
related with skeletal muscle glucose uptake, both in the
presence and absence of hypertension.136 Despite normal
hormonal signaling in muscles, insulin-stimulated glucose
uptake is impaired in patients with chronic heart failure.137
Chronic OSA can lead to some degree of heart failure, and
this complication, in turn, reduces flow to the hindquar-
ters and limits the vascular flow capacity of mainly high
oxidative muscle fibers, ie, those most sensitive to insu-
lin.138 Therefore, heart failure reduces the proportion of cap-
illaries supporting continuous whole blood flow.139 Inter-
estingly, left ventricular dysfunction without concomitant
heart failure may be sufficient to induce disturbances in
skeletal muscle arteriolar dimensions and reactivity, sug-
gesting that perturbations in muscle may start very early.140
Systemic blood pressure, on the other hand, is accom-
panied by microvascular rarefaction in skeletal muscle and
impaired vasodilatation.141 This, in addition to a decrease
in type I oxidative muscle fibers and an increase in the di-
ameter of fast-twitch fibers, would increase the diffusion
distance for insulin to its sites of action, explaining at least
in part how hypertension could be linked to peripheral
IR.142–144 Indeed, serum cholesterol and glucose are in-
versely related to the percent of highly insulin-sensitive
type I fibers in hypertensive patients, whereas negative cor-
relations were found between the degree of capillarization
and glucose, cholesterol, and uric acid. Under conditions
of stimulation, the reactivity of skeletal muscle arterioles
is limited in hypertensive rats.145,146 Impaired endothelium-
dependent vasodilatation of small arteries and arterioles is
also seen in experimental IH.47,147To what extent these lim-
ited reactions of the resistance vessels are responsible for
IR in HT is still unclear, but they are clearly related.148,149
Microcirculation as a Key Player?
A somewhat provocative hypothesis should be discussed
here: if we consider the group of nervous, chemical, and
vascular factors found in OSA, all ingredients are present
that favor malfunctioning of the microcirculation. It is in-
teresting to note that the resistance vessels, and not the
larger conduit vessels, are the site of impaired endothelium-
dependent vasodilatation in OSA.88 The question then is
if—and how—impaired microcirculation can lead to—and
aggravate—the cardiovascular disorders observed in OSA
patients.
It has been proposed that microvascular (arterioles, cap-
illaries) defects could precede or act in concert with IR.150,151
In skeletal muscle, each capillary supplies several muscle
fibers; therefore, one might expect capillary rarefaction, as
seen in hypertension or heart failure, to be one of these de-
fects. Moreover, because several (10 to 15) capillaries are
grouped into functional units and each unit is controlled
by one terminal arteriole, the recruitment of capillaries
upon demand depends on the reactivity of the feeding ar-
teriole. Therefore, defects in arteriolar reactivity to nerv-
ous inputs or local hemodynamic forces, such as shear
stress, may impair the recruitment and/or perfusion of cap-
illaries. Among substances involved in capillary recruit-
ment, insulin itself has hemodynamic properties at the mi-
crovascular level; low insulin concentrations that do not
increase bulk blood flow dilate terminal arterioles and in-
crease capillary flow.152–154 It has been suggested that small
increases in insulin from meals, by opening additional mi-
crocirculatory units, “open its own way” for reaching skel-
etal muscle cells in order to store excess postprandial glu-
cose.155 Other physiological regulatory processes that are
specific for the microcirculation, such as precapillary ar-
teriolar vasomotion, may also be defective and lead to a
patchy and inadequate tissue perfusion.156 Any defect in
these processes leads to reduced functional capillary den-
sity and thereby to impaired muscle glucose delivery and
uptake, which consequently favors the development of IR.
Although this hypothesis still needs to be fully con-
firmed,157–159 the profile of OSA fits largely with this theory.
Today, OSAs can be reasonably well simulated in animals,
new devices allow microcirculation to be measured
noninvasively in humans, and clinical awareness of the fre-
quency and importance of this pathology is sharply grow-
ing. Therefore, targeted microcirculatory investigations
should be implemented to evaluate the importance of this
anatomical entity.
CONCLUSION / PERSPECTIVES
The explosion of data within the past 5 years indicates
that OSA is a “young” investigated disease, inasmuch as
its potential harmfulness is concerned. The classical view
of this pathology has largely been modified in recent years
by demonstrating that it is a serious medical situation linked
with behavioral, anatomical, and physiological disturbances
leading to metabolic and cardiovascular complications.
Moreover, it appears to be responsible for a non-negligi-
ble fraction of car accidents and human deaths as a conse-
260
CLINICS 2006;61(3):253-66Obstructive sleep apnea and insulin resistance: a role for microcirculation?
Wiernsperger N et al.
quence of daytime sleepiness.
The development of continuous positive airway pres-
sure (CPAP) as a therapy for OSA has generated mixed re-
sults, even if one excludes the limited patient compliance
due to discomfort. Thus, while surrogate endpoints such as
AHI5, TNFα65, reactive oxygen species,87,93 or endothelial
function were improved by CPAP, some global clinical out-
comes have not necessarily shown the same benefit.5,160
Moreover, for various reasons, a good portion of the gen-
eral population has mild OSA and, as such, is at risk for
CVD but is not amenable to CPAP therapy. It is therefore
important to know much more about this widespread and
harmful pathology in order to possibly develop alternative
therapeutic strategies.
As for most domains, available data in OSA are partly
conflicting. This field of investigation is only beginning and
needs more experimental models, confirmations of prelimi-
nary findings, and target-directed clinical protocols. In the
present review, we have tried to give a broad and updated
objective state of our actual knowledge to date. Neverthe-
less, recent data indicates that OSA may not only be a con-
sequence of IR or obesity but might also be causal, making
these relationships bidirectional. If true, this would mean that
not only could OSA aggravate existing IR and its related vas-
cular abnormalities, but it could also directly induce an ar-
ray of perturbations favoring—or directly generating—a state
much resembling the well-known metabolic syndrome. We
believe that, although the amount of sound data is still lim-
ited, the convincing nature of this data supports this latter
hypothesis. In view of the list of OSA-modified parameters,
we also propose a hypothesis according to which microcir-
culation might play a key role in this pathology.
RESUMO
Wiernsperger N, Nivoit P, Bouskela E. Apnéia obstrutiva
do sono e resistência à insulina: qual o papel da
microcirculação? Clinics. 2006;61(3):253-66.
A apnéia obstrutiva do sono é um problema médico cujo re-
conhecimento tem aumentado. As últimas pesquisas mostran-
do sua freqüência na população em geral e seu importante
papel metabólico, vascular e comportamental aumentou o
número e a natureza das investigações revelando, assim, no-
vos aspectos que abrem caminhos para estudos. Embora a
apnéia obstrutiva do sono seja um fenômeno bem conheci-
do acompanhando diabetes e obesidade, novas descobertas
sugerem que esta relação causal pode também ser verdadei-
ra no sentido inverso. Na realidade, a apnéia obstrutiva do
sono pode ser o marco inicial ou primário que induz ou agra-
va uma série de distúrbios vasculares e metabólicos que se
aproximam da síndrome metabólica. Esta revisão discutirá
mecanismos estabelecidos e potenciais responsáveis por es-
tas mudanças. A apnéia obstrutiva do sono parece realmen-
te juntar todos os elementos necessários para induzir resis-
tência à insulina, hipertensão e possivelmente insuficiência
cardíaca. Após análise cuidadosa destas modificações, con-
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